Methods for enhancing anti-tumor antibody therapy

US9005619B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Holbrook Kohrt · San Francisco, US
• Roch Houot · Rennes, FR
• Ronald Levy · Palo Alto, US
• Arash Ash Alizadeh · San Mateo, US
• Matthew J. Goldstein · Hillsborough, US
• James Torchia · Stanford, US

Key dates

• Filing date: Dec 7, 2010
• Grant date: Apr 14, 2015
• Expiry date: Dec 7, 2030

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70578
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.